Vitronectin inhibits the thrombotic response to arterial injury in mice

Blood

Volumn 93, Issue 6, 1999, Pages 1825-1830

  Fay, William P ^a,b   Parker, Andrew C ^a   Ansari, Maria N ^a   Zheng, Xianxian ^a   Ginsburg, David ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN; INTEGRIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN; VITRONECTIN;

ANIMAL EXPERIMENT; ARTERY INJURY; ARTICLE; BLOOD VESSEL REACTIVITY; CELL MIGRATION; CONTROLLED STUDY; FIBRINOLYSIS; HISTOPATHOLOGY; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN DENATURATION; PROTEIN PURIFICATION; THROMBOCYTE AGGREGATION; THROMBOSIS;

EID: 0033559292     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.6.1825.406k37_1825_1830     Document Type: Article

References (41)

1. Tomasini BR, Mosher DF: Vitronectin. Prog Hemost Thromb 10:269, 1991
2. Preissner KT: Structure and biological role of vitronectin. Annu Rev Cell Biol 7:275, 1991
3. Cherny RC, Honan MA, Thiagarajan P: Site-directed mutagenesis of the Arginine-Glycine-Aspartic acid in vitronectin abolishes cell adhesion. J Biol Chem 268:13:9725, 1993
4. Declerck PJ, De Mol M, Alessi MC, Baudner S, Paques EP, Preissner KT, Muller-Berghaus G, Collen D: Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem 263:15454, 1988
5. Kanse SM, Kost C, Wilhelm OG, Andreasen PA, Preissner KT: The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp Cell Res 224:344, 1996
6. Izumi M, Shimo-Oka T, Morishita N, Ii I, Hayashi I: Identification of the collagen-binding domain of vitronectin using monoclonal antibodies. Cell Struct Funct 13:217, 1988
7. Tschopp J, Masson D, Schafer S, Peitsch M, Preissner KT: The heparin binding domain of S-protein/vitronectin binds to complement components C7, C8, C9 and perform from cytolytic T-cells and inhibits their lytic activities. Biochemistry 27:4103, 1988
8. Preissner KT, Muller-Berghaus G: Neutralization and binding of heparin by S protein/vitronectin in the inhibition of factor Xa by antithrombin III. Involvement of an inducible heparin binding domain of S protein/vitronectin. J Biol Chem 262:12247, 1987
9. Preissner KT, Seiffert D: Role of vitronectin and its receptors in haemostasis and vascular remodeling. Thromb Res 89:1, 1998
10. Seiffert D, Smith JW: The cell adhesion domain in plasma vitronectin is cryptic. J Biol Chem 272:21:13705, 1997
11. Tomasini BR, Mosher DF: Conformational states of vitronectin: Preferential expression of an antigenic epitope when vitronectin is covalently and noncovalently complexed with thrombin-antithrombin III or treated with urea. Blood 72:903, 1988
12. Seiffert D, Loskutoff DJ: Type 1 plasminogen activator inhibitor induces multimerization of plasma vitronectin - A suggested mechanism for the generation of the tissue form of vitronectin in vivo. J Biol Chem 271:29644, 1996
13. Seiffert D, Schleef RR: Two functionally distinct pools of vitronectin (Vn) in the blood circulation: Identification of a heparin-binding competent population of Vn within platelet α-granules. Blood 88:552, 1996
14. 3 binding to vitronectin. Nature 383:441, 1996
15. Waltz DA, Natkin LR, Fujita RM, Wei Y, Chapman HA: Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J Clin Invest 100:58, 1997
16. Thiagarajan P, Kelly KL: Exposure of binding sites for vitronectin on platelets following stimulation. J Biol Chem 263:3035, 1988
17. Asch E, Podack E: Vitronectin binds to activated human platelets and plays a role in platelet aggregation. J Clin Invest 85:1372, 1990
18. Mohri H, Ohkubo T: How vitronectin binds to activated glycoprotein IIb-IIIa complex and its function in platelet aggregation. Am J Clin Pathol 96:605, 1991
19. Ehrlich HJ, Gebbink RK, Keijer J, Linders M, Preissner KT, Pannekoek H: Alteration of serpin specificity by a protein cofactor. Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties. J Biol Chem 265:13029, 1990
20. Naski MC, Lawrence DA, Mosher DF, Podor TJ, Ginsburg D: Kinetics of inactivation of alpha-thrombin by plasminogen activator inhibitor-1. J Biol Chem 268:12367, 1993
21. Preissner KT, de Boer H, Pannekoek H, de Groot PG: Thrombin regulation by physiological inhibitors: the role of vitronectin. Semin Thromb Hemost 22:165, 1996
22. Zheng X, Saunders TL, Camper SA, Samuelson LC, Ginsburg D: Vitronectin is not essential for normal mammalian development and fertility. Proc Natl Acad Sci USA 92:12426, 1995
23. Carmeliet P, Kieckens L, Schoonjans L, Ream B, Nuffelen A, Prendergast G, Cole M, Bronson R, Collen D, Mulligan R: Plasminogen activator inhibitor-1 gene deficient mice. I. Generation by homologous recombination and characterization. J Clin Invest 92:2746, 1993
24. Eitzman DT, McCoy RD, Zheng X, Fay WP, Shen T, Ginsburg D, Simon RH: Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 97:232, 1996
25. Farrehi PM, Ozaki CK, Carmeliet P, Fay WP: Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice. Circulation 97:1002, 1998
26. Kurz KD, Main BW, Sandusky GE: Rat model of arterial thrombosis induced by ferric chloride. Thromb Res 60:269, 1990
27. Carmeliet P, Moons L, Stassen J, De Mol M, Bouche A, van den Oord J, Kockx M, Collen D: Vascular wound healing and neointima formation induced by perivascular electric injury in mice. Am J Pathol 150:761, 1997
28. Walkowiak B, Kesy A, Michalec L: Microplate reader - A convenient tool in studies of blood coagulation. Thromb Res 87:95, 1997
29. Fay WP, Eitzman DT, Shapiro AD, Madison EL, Ginsburg D: Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor-1 dependent and independent mechanisms. Blood 83:351, 1994
30. Saleem A, Krieg AF, Fretz K: Improved micromethod for plasma fibrinogen unaffected by heparin therapy. Am J Clin Pathol 63:426, 1975
31. Exner T, Burridge J, Power P, Rickard KA: An evaluation of currently available methods for plasma fibrinogen. Am J Clin Pathol 71:521, 1979
32. Mann KG: Promrombin and Thrombin, in Colman RW, Hirsh J, Marder VJ, Salzman EW (eds): Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia, PA, Lippincott, 1994, p 184
33. Marsh LE, Lewis SD, Lehman ED, Gardell SJ, Motzel SL, Lynch JJ Jr: Assessment of thrombin inhibitor efficacy in a novel rabbit model of simultaneous arterial and venous thrombosis. Thromb Haemost 79:656, 1998
34. Denis C, Methia N, Frenette PS, Rayburn H, Ullman-Cullere M, Hynes RO, Wagner DD: A mouse model of severe von Willebrand disease: Defects in hemostasis and thrombosis. Proc Natl Acad Sci USA 95:9524, 1998
35. Balla G, Vercellotti GM, Eaton JW, Jacob HS: Iron loading of endothelial cells augments oxidant damage. J Lab Clin Med 116:546, 1990
36. Ambrosio G, Tritto I, Golino P: Reactive oxygen metabolites and arterial thrombosis. Cardiovasc Res 34:445, 1997
37. Halliwell B: Superoxide, iron, vascular endothelium and reperfusion injury. Free Rad Res Commun 5:315, 1989
38. Rote WE, Oldeschulte GL, Dempsey EM, Vlasuk GP: Evaluation of a novel small protein inhibitor of the blood coagulation factor VIIa/tissue factor complex in animal models of arterial and venous thrombosis. Circulation 94:I-695, 1996 (abstr)
39. Izumi M, Yamada KM, Hayashi M: Vitronectin exists in two structurally and functionally distinct forms in human plasma. Biochim Biophys Acta 990:101, 1989
40. Parker CJ, Stone OL, White VF, Bernshaw NJ: Vitronectin (S protein) is associated with platelets. Br J Haematol 71:245, 1989
41. van Aken BE, Seiffert D, Thinnes T, Loskutoff DJ: Localization of vitronectin in the normal and atherosclerotic human vessel wall. Histochem Cell Biol 107:313, 1997